Liver Disease: A nontumorigenic variant of FGF19 treats cholestatic liver diseases

Science Translational Medicine

Volumn 6, Issue 247, 2014, Pages

  Luo, Jian ^a   Ko, Brian ^a   Elliott, Michael ^a   Zhou, Mei ^a   Lindhout, Darrin A ^a   Phung, Van ^a   To, Carmen ^a   Learned, R Marc ^a   Tian, Hui ^a   DePaoli, Alex M ^a   Ling, Lei ^a  

^a NGM Biopharmaceuticals Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7ALPHA HYDROXYCHOLEST 4 EN 3 ONE; CHOLESTEROL 7ALPHA MONOOXYGENASE; FIBROBLAST GROWTH FACTOR 19; M70 PROTEIN; PLACEBO; UNCLASSIFIED DRUG; 7 ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; BILE ACID; BIOLOGICAL MARKER; CHOLAGOGUE; CHOLEST 4 EN 3 ONE; CYP7A1 PROTEIN, HUMAN; CYP7A1 PROTEIN, MOUSE; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; MESSENGER RNA; RECOMBINANT PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; CHOLESTATIC LIVER DISEASE; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; EXTRAHEPATIC BILE DUCT OBSTRUCTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VIVO STUDY; INTRAHEPATIC CHOLESTASIS; LIVER DISEASE; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; AUSTRALIA; BIOSYNTHESIS; BLOOD; CHOLESTASIS, EXTRAHEPATIC; CHOLESTASIS, INTRAHEPATIC; DISEASE MODEL; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC VARIABILITY; GENETICS; LIVER; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT; YOUNG ADULT;

ADULT; ANIMALS; AUSTRALIA; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS, EXTRAHEPATIC; CHOLESTASIS, INTRAHEPATIC; CHOLESTENONES; CHOLESTEROL 7-ALPHA-HYDROXYLASE; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; DOWN-REGULATION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE TRANSFER TECHNIQUES; GENETIC VARIATION; HEALTHY VOLUNTEERS; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; RECOMBINANT PROTEINS; RISK ASSESSMENT; RNA, MESSENGER; YOUNG ADULT;

EID: 84922726981     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009098     Document Type: Article

References (53)

1. A. F. Hofmann, Bile acids: Trying to understand their chemistry and biology with the hope of helping patients. Hepatology 49, 1403-1418 (2009).
2. M. M. Kaplan, M. E. Gershwin, Primary biliary cirrhosis. N. Engl. J. Med. 353, 1261-1273 (2005). (Pubitemid 41345948)
3. G. M. Hirschfield, E. J. Heathcote, M. E. Gershwin, Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 139, 1481-1496 (2010).
4. S. S. Strautnieks, L. N. Bull, A. S. Knisely, S. A. Kocoshis, N. Dahl, H. Arnell, E. Sokal, K. Dahan, S. Childs, V. Ling, M. S. Tanner, A. F. Kagalwalla, A. Németh, J. Pawlowska, A. Baker, G. Mieli-Vergani, N. B. Freimer, R. M. Gardiner, R. J. Thompson, A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 20, 233-238 (1998). (Pubitemid 28507666)
5. J. M. de Vree, E. Jacquemin, E. Sturm, D. Cresteil, P. J. Bosma, J. Aten, J. F. Deleuze, M. Desrochers, M. Burdelski, O. Bernard, R. P. Oude Elferink, M. Hadchouel, Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl. Acad. Sci. U. S. A. 95, 282-287 (1998). (Pubitemid 28103945)
6. K. Lindor, Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N. Engl. J. Med. 357, 1524-1529 (2007).
7. D. W. Russell, Fifty years of advances in bile acid synthesis and metabolism. J. Lipid Res. 50(Suppl.), S120-S125 (2009).
8. M. J. Potthoff, S. A. Kliewer, D. J. Mangelsdorf, Endocrine fibroblast growth factors 15/19 and 21: From feast to famine. Genes Dev. 26, 312-324 (2012).
9. B. Angelin, T. E. Larsson, M. Rudling, Circulating fibroblast growth factors as metabolic regulators-A critical appraisal. Cell Metab. 16, 693-705 (2012).
10. M. H. Xie, I. Holcomb, B. Deuel, P. Dowd, A. Huang, A. Vagts, J. Foster, J. Liang, J. Brush, Q. Gu, K. Hillan, A. Goddard, A. L. Gurney, FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11, 729-735 (1999). (Pubitemid 29460470)
11. B. C. Lin, M. Wang, C. Blackmore, L. R. Desnoyers, Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 282, 27277-27284 (2007). (Pubitemid 47501977)
12. X. Wu, H. Ge, J. Gupte, J. Weiszmann, G. Shimamoto, J. Stevens, N. Hawkins, B. Lemon, W. Shen, J. Xu, M. M. Veniant, Y. S. Li, R. Lindberg, J. L. Chen, H. Tian, Y. Li, Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 282, 29069-29072 (2007). (Pubitemid 350043330)
13. H. Kurosu, M. Choi, Y. Ogawa, A. S. Dickson, R. Goetz, A. V. Eliseenkova, M. Mohammadi, K. P. Rosenblatt, S. A. Kliewer, M. Kuro-o, Tissue-specific expression of bKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687-26695 (2007). (Pubitemid 47501965)
14. T. Inagaki, M. Choi, A. Moschetta, L. Peng, C. L. Cummins, J. G. McDonald, G. Luo, S. A. Jones, B. Goodwin, J. A. Richardson, R. D. Gerard, J. J. Repa, D. J. Mangelsdorf, S. A. Kliewer, Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217-225 (2005).
15. C. Yu, F. Wang, M. Kan, C. Jin, R. B. Jones, M. Weinstein, C. X. Deng, W. L. McKeehan, Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275, 15482-15489 (2000). (Pubitemid 30337280)
16. S. Ito, T. Fujimori, A. Furuya, J. Satoh, Y. Nabeshima, Y. Nabeshima, Impaired negative feedback suppression of bile acid synthesis in mice lacking bKlotho. J. Clin. Invest. 115, 2202-2208 (2005). (Pubitemid 41134162)
17. J. A. Holt, G. Luo, A. N. Billin, J. Bisi, Y. Y. McNeill, K. F. Kozarsky, M. Donahee, D. Y. Wang, T. A. Mansfield, S. A. Kliewer, B. Goodwin, S. A. Jones, Definition of a novel growth factordependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581-1591 (2003). (Pubitemid 36828786)
18. A. L. Wu, S. Coulter, C. Liddle, A. Wong, J. Eastham-Anderson, D. M. French, A. S. Peterson, J. Sonoda, FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLOS One 6, e17868 (2011).
19. D. M. French, B. C. Lin, M. Wang, C. Adams, T. Shek, K. Hötzel, B. Bolon, R. Ferrando, C. Blackmore, K. Schroeder, L. A. Rodriguez, M. Hristopoulos, R. Venook, A. Ashkenazi, L. R. Desnoyers, Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLOS One 7, e36713 (2012).
20. I. Uriarte, M. G. Fernandez-Barrena, M. J. Monte, M. U. Latasa, H. C. Chang, S. Carotti, U. Vespasiani-Gentilucci, S. Morini, E. Vicente, A. R. Concepcion, J. F. Medina, J. J. Marin, C. Berasain, J. Prieto, M. A. Avila, Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 62, 899-910 (2013).
21. K. Nicholes, S. Guillet, E. Tomlinson, K. Hillan, B. Wright, G. D. Frantz, T. A. Pham, L. Dillard-Telm, S. P. Tsai, J. P. Stephan, J. Stinson, T. Stewart, D. M. French, A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 160, 2295-2307 (2002). (Pubitemid 34663420)
22. E. T. Sawey, M. Chanrion, C. Cai, G. Wu, J. Zhang, L. Zender, A. Zhao, R. W. Busuttil, H. Yee, L. Stein, D. M. French, R. S. Finn, S. W. Lowe, S. Powers, Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347-358 (2011).
23. M. Zhou, X. Wang, V. Phung, D. A. Lindhout, K. Mondal, J. Y. Hsu, H. Yang, M. Humphrey, X. Ding, T. Arora, R. M. Learned, A. M. DePaoli, H. Tian, L. Ling, Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 74, 3306-3316 (2014).
24. H. Zhang, J. Xie, Q. Xie, J. M. Wilson, G. Gao, Adenovirus-adeno- associated virus hybrid for large-scale recombinant adeno-associated virus production. Hum. Gene Ther. 20, 922-929 (2009).
25. L. Ling, D. A. Lindhout, Compositions, uses and methods for treatment of metabolic disorders and diseases, U. S. Patent 2013/0023474A1 (2013).
26. A. K. Zaiss, Q. Liu, G. P. Bowen, N. C. Wong, J. S. Bartlett, D. A. Muruve, Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76, 4580-4590 (2002). (Pubitemid 34309593)
27. V. M. Rivera, X. Ye, N. L. Courage, J. Sachar, F. Cerasoli Jr., J. M. Wilson, M. Gilman, Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc. Natl. Acad. Sci. U. S. A. 96, 8657-8662 (1999). (Pubitemid 29354847)
28. J. A. Marrero, H. B. El-Serag, Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology 53, 1060-1061; author reply 1061-1062 (2011).
29. M. L. Chang, C. T. Yeh, P. Y. Chang, J. C. Chen, Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation. World J. Gastroenterol. 11, 4167-4172 (2005).
30. J. S. Crippin, K. D. Lindor, R. Jorgensen, B. A. Kottke, J. M. Harrison, P. A. Murtaugh, E. R. Dickson, Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: What is the risk? Hepatology 15, 858-862 (1992).
31. T. C. Su, J. J. Hwang, J. H. Kao, Hypercholesterolemia in primary biliary cirrhosis. N. Engl. J. Med. 357, 1561-1562 (2007).
32. E. Halilbasic, T. Claudel, M. Trauner, Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J. Hepatol. 58, 155-168 (2013).
33. L. N. Bull, M. J. van Eijk, L. Pawlikowska, J. A. DeYoung, J. A. Juijn, M. Liao, L. W. Klomp, N. Lomri, R. Berger, B. F. Scharschmidt, A. S. Knisely, R. H. Houwen, N. B. Freimer, A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 18, 219-224 (1998). (Pubitemid 28117258)
34. G. Sauter, F. Berr, U. Beuers, S. Fischer, G. Paumgartner, Serum concentrations of 7a-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 24, 123-126 (1996). (Pubitemid 26249423)
35. C. Gälman, I. Arvidsson, B. Angelin, M. Rudling, Monitoring hepatic cholesterol 7a-hydroxylase activity by assay of the stable bile acid intermediate 7a-hydroxy-4-cholesten-3-one in peripheral blood. J. Lipid Res. 44, 859-866 (2003).
36. J. Hyeon, S. Ahn, J. J. Lee, D. H. Song, C. K. Park, Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig. Dis. Sci. 58, 1916-1922 (2013).
37. F. G. Schaap, N. A. van der Gaag, D. J. Gouma, P. L. Jansen, High expression of the bile salthomeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49, 1228-1235 (2009).
38. K. H. Hasegawa Y, M. Kawai, T. Ueno, Y. Miyahara, FGF19 is aberrantly expressed in cholestatic hepatocytes and its signaling pathways were downregulated in biliary atresia children. Hepatology 58, 802A (2013).
39. L. R. Desnoyers, R. Pai, R. E. Ferrando, K. Hötzel, T. Le, J. Ross, R. Carano, A. D'Souza, J. Qing, I. Mohtashemi, A. Ashkenazi, D. M. French, Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 27, 85-97 (2008).
40. K. H. Song, T. Li, E. Owsley, S. Strom, J. Y. Chiang, Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7a-hydroxylase gene expression. Hepatology 49, 297-305 (2009).
41. S. W. Van Mil, A. Milona, P. H. Dixon, R. Mullenbach, V. L. Geenes, J. Chambers, V. Shevchuk, G. E. Moore, F. Lammert, A. G. Glantz, L. A. Mattsson, J. Whittaker, M. G. Parker, R. White, C. Williamson, Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133, 507-516 (2007). (Pubitemid 47187340)
42. F. Chen, M. Ananthanarayanan, S. Emre, E. Neimark, L. N. Bull, A. S. Knisely, S. S. Strautnieks, R. J. Thompson, M. S. Magid, R. Gordon, N. Balasubramanian, F. J. Suchy, B. L. Shneider, Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126, 756-764 (2004). (Pubitemid 38298324)
43. M. G. Silveira, K. D. Lindor, Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin. Pharmacother. 15, 365-372 (2014).
44. S. Modica, M. Petruzzelli, E. Bellafante, S. Murzilli, L. Salvatore, N. Celli, G. Di Tullio, G. Palasciano, T. Moustafa, E. Halilbasic, M. Trauner, A. Moschetta, Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142, 355-365.e4 (2012).
45. B. Kong, L. Wang, J. Y. Chiang, Y. Zhang, C. D. Klaassen, G. L. Guo, Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56, 1034-1043 (2012).
46. Y. Liang, Z. Yang, R. Zhong, Primary biliary cirrhosis and cancer risk: A systematic review and meta-analysis. Hepatology 56, 1409-1417 (2012).
47. X. Wu, H. Ge, B. Lemon, S. Vonderfecht, H. Baribault, J. Weiszmann, J. Gupte, J. Gardner, R. Lindberg, Z. Wang, Y. Li, Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc. Natl. Acad. Sci. U. S. A. 107, 14158-14163 (2010).
48. C. R. Pullinger, C. Eng, G. Salen, S. Shefer, A. K. Batta, S. K. Erickson, A. Verhagen, C. R. Rivera, S. J. Mulvihill, M. J. Malloy, J. P. Kane, Human cholesterol 7a-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110, 109-117 (2002). (Pubitemid 34743471)
49. J. D. Nolan, I. M. Johnston, J. R. Walters, Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: A new perspective. Expert Rev. Gastroenterol. Hepatol. 7, 49-56 (2013).
50. M. Lenicek, D. Duricova, V. Komarek, B. Gabrysova, M. Lukas, Z. Smerhovsky, L. Vitek, Bile acid malabsorption in inflammatory bowel disease: Assessment by serum markers. Inflamm. Bowel Dis. 17, 1322-1327 (2011).
51. B. S. Reddy, Role of bile metabolites in colon carcinogenesis. Animal models. Cancer 36, 2401-2406 (1975).
52. S. Yoshimoto, T. M. Loo, K. Atarashi, H. Kanda, S. Sato, S. Oyadomari, Y. Iwakura, K. Oshima, H. Morita, M. Hattori, K. Honda, Y. Ishikawa, E. Hara, N. Ohtani, Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97-101 (2013).
53. C. Cicione, C. Degirolamo, A. Moschetta, Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology 56, 2404-2411 (2012).